Ciara Kennedy was Appointed as President and Chief Executive Officer at Amplyx Pharmaceuticals

Date of management change: June 15, 2015 

What Happened?

San Diego, CA-based Amplyx Pharmaceuticals appointed Ciara Kennedy as President and Chief Executive Officer

 

About the Company

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.

 

About the Person

Ciara Kennedy is the Chief Operating Officer at Amplyx Pharmaceuticals. She is an energetic leader with a proven track record of delivering significant results and advancing therapeutic/diagnostic programs across multiple therapeutic areas (inc. oncology, immunology and CNS) and stages of development (from research through FDA approval). She is also skilled at establishing operational excellence within culturally diverse environments, geographically separate teams within and across companies. She has superior interpersonal skills leading to effective management and development of internal management and corporate partners. She has also successfully led diagnostic service organization with P&L responsibility, decreasing operating costs, increasing net revenues and ultimately divestiture of business unit.

 

Info Source

Press Release

 
 

Other IT executives who recently changed jobs as well: Molchan Courtney, Plate Gabriele, BIRTZ BJ, Giunta Karol, Orner Carolyn, Suarez Darcy, Sander Emily, Byler Chad, Barber Jeff, Berridge Jessica, Petersen Roger

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.